Based on these reported findings, IL-36α, IL-36β and IL-36γ present promising therapeutic targets in CRC and NSCLC, although any therapeutic development must be considered in the context of these cytokines’ ability to also act as tumour suppressors. Here, IL36G is linked to neoplasm.